metricas
covid
Buscar en
Medicina de Familia. SEMERGEN
Toda la web
Inicio Medicina de Familia. SEMERGEN Betabloqueantes e insuficiencia cardíaca
Journal Information
Vol. 30. Issue 9.
Pages 470-473 (October 2004)
Share
Share
Download PDF
More article options
Vol. 30. Issue 9.
Pages 470-473 (October 2004)
Full text access
Betabloqueantes e insuficiencia cardíaca
Visits
11146
S. García de Franciscoa,
Corresponding author
saragdf@wanadoo.es

Correspondencia: S. García de Francisco. Av. Juán Andrés 44, 2.o D. 28035 Madrid.
, M. Taboada Taboadab, A. García de Franciscoc
a Médico de Familia. Centro de Salud Fuencarral. Madrid
b Especialista en Cardiología. Centro de Salud Fuencarral. Madrid
c Médico de Familia. Centro de Salud Emigrantes. Madrid
This item has received
Article information

Presentamos el caso de un varón de 75 años de edad que, tras haber sufrido un infarto agudo de miocardio, es dado de alta hospitalaria con carvedilol, furosemida, captopril, espirinolactona y acenocumarol. Acude a la consulta con astenia intensa, disnea con ortopnea e hipotensión. El diagnóstico fue de hipotensión y descompensación de la insuficiencia cardíaca en posible relación con la introducción de betabloqueantes tras un infarto agudo de miocardio.

Tras realizar un ajuste terapéutico, fundamentalmente basado en la reducción de la dosis de carvedilol, el paciente fue mejorando progresivamente, restableciendo finalmente la dosis inicial de carvedilol una vez estabilizado el paciente.

Palabras clave:
betabloqueantes
insuficiencia cardíaca
cardiopatía isquémica
hipertensión arterial
DiscusiÓn

La eficacia de los betabloqueantes en la prevención de la muerte súbita y en la mejoría funcional de los pacientes en grado II-III de insuficiencia cardíaca está ampliamente demostrada. La indicación de estos fármacos corresponde al cardiólogo, pero el médico de Atención Primaria debe conocer su manejo, indicaciones, efectos secundarios y realizar su seguimiento, ya que será quien siga estrechamente la evolución del paciente.

Se discuten las indicaciones, dosis, manejo y efectos secundarios de los betabloqueantes en la insuficiencia cardíaca.

We present the case of a 75 year old male who, after suffering acute myocardial infarction, was discharged with carvedilol, furosemide, captopril, spirinolactone and acenocumarol. He came to the medical visit with intense asthenia, dyspnea with orthopnea and hypotension. The diagnosis was hypotension and heart failure decompensation possibly related with the introduction of beta blockers after an acute myocardial infarction.

After performing therapeutic adjustment, fundamentally based on the reduction of the carvedilol dose, the patient progressively improved, and the initial carvedilol dose was finally reestablishing once the patient was stabilized.

Discussion

. The efficacy of beta blockers in the prevention of sudden death and in functional improvement of heart failure grade II-III patients is widely demonstrated. Indication of these drugs corresponds to the cardiologist, but the Primary Health Care physician should know its management, indications, side effects and should perform a followup, since he will be the one to closely follow the patient's evolution. The indications, dose, management and side effects of beta blockers in heart failure are discussed.

Key words:
beta blockers
heart failure
ischemic heart disease
arterial hypertension
Full text is only aviable in PDF
Bibliografía
[1.]
K.L. Grady, K. Dracup, G. Kennedy, D.K. Moser, M. Piano, L.W. Stevenson, et al.
Team Management of Patients With Heart Failure. A Statement for Healthcare Professionals From the Cardiovascular Nursing Council of the American Heart Association.
Circulation, 102 (2000), pp. 2443-2456
[2.]
The RALES Investigators.
Effectiveness of spirinolactona added to an angiotensin converting enzyme inhibitor and a loop diuretic for sever chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol, 78 (1996), pp. 902-907
[3.]
E. Lonn, R. Mckelvie.
Drug treatment in heart failure.
BMJ, 320 (2000), pp. 1188-1192
[4.]
CIBIS Investigators and Comittees.
A randomized trial of â-blockade in heart failure: The Cardiac Insuficiency Bisoprolol Study (CIBIS).
Circulation, 90 (1994), pp. 1765-1773
[5.]
CIBIS II Investigators.
The Cardiac Insuficiency Bisoprolol Study II: a randomized trial.
Lancet, 353 (1999), pp. 9-13
[6.]
MERIT-HF Study Group.
Effect of metoprolol in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).
Lancet, 353 (1999), pp. 2001-2007
[7.]
E.M. Gilbert, N.H. Shusterman.
for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality inpatients with chronic heart failure.
N Engl J Med, 334 (1996), pp. 1.349-1.355
[8.]
Australian/New Zeland Heart Failure Research Collaborative Group.
Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.
Lancet, 349 (1997), pp. 375-380
[9.]
F. Waagstein, M.R. Bristow, K. Swedberg, F. Camerini, M.B. Fowler, M.A. Silver, et al.
Metoprolol in Dilated Cardiomyopathy (MDC). Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomiopathy.
Lancet, 342 (1993), pp. 1441-1446
[10.]
P. Lechat, M. Packer, S. Chalon, M. Cucherat, T. Arab, J.P. Boissel.
Clinical effects of â-adrenergic blockade in chronic heart failure.
Circulation, 98 (1998), pp. 1184-1191
[11.]
N. Sharpe.
Betablockers in heart failure. Future directions.
Eur Heart J, 17 (1996), pp. 39-42
[12.]
Consensus recommendations for themanagements of chronic heart failure.
On behalf of the membership of the advisory council to im-prove outcomes nationwide in heart failure.
Am J Cardiol, 83 (1999), pp. 1A-38A
[13.]
G.R. Gibbs, M.K. Davies, G.Y. Lip.
Management: digoxin and other inotropes β-blockers and antiarrythmic and antithrombotic treatment.
BMJ, 320 (2000), pp. 495-498
[14.]
G.E. Newton, J.D. Packer.
Acute effects of β-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure.
Circulation, 94 (1996), pp. 353-358
[15.]
M. Gomberg-Mantland, D.A. Baran, V. Fuster.
Treatment of congestive heart failure guidelines for the primary care physician and the heart failure specialist.
Ach Intern Med, 161 (2001), pp. 342-352
[16.]
J.M. Lobos, P. Conthe.
Bloqueadores beta en la insuficiencia cardiaca.
FMC, 7 (2000), pp. 123-131
[17.]
W. Bolten.
Current state of treatment and prevention of gastroduodenal side effects of non-steroidal antirheumatic drugs.
Leber Magen Darm, 21 (1991), pp. 193-194
Copyright © 2004. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos